Drug Profile
Research programme: janus kinase inhibitors - Aclaris Therapeutics
Alternative Names: Baricitinib - Aclaris Therapeutics; Decernotinib - Aclaris Therapeutics; JAK inhibitors; Ruxolitinib - Aclaris Therapeutics; Tofacitinib - Aclaris TherapeuticsLatest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator Columbia University
- Developer Aclaris Therapeutics
- Class Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alopecia; Vitiligo
Most Recent Events
- 07 Sep 2023 Discontinued - Preclinical for Vitiligo in USA (unspecified route) (Aclaris Therapeutics pipeline; September 2023)
- 07 Sep 2023 Discontinued for Alopecia in USA (unspecified route) (Aclaris Therapeutics pipeline; September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Vitiligo in USA